Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
This article was originally published in The Pink Sheet Daily
Executive Summary
Fee rates for biosimilars could be decoupled from new drug user fees in order to provide more predictable revenue stream.
You may also be interested in...
Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
Percentage of personnel spending as a proportion of biosimilar review costs dropped more than 17% over three-year period as equipment and other spending more than doubled.
Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
Percentage of personnel spending as a proportion of biosimilar review costs dropped more than 17% over three-year period as equipment and other spending more than doubled.
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.